-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Moderna, Lowers Price Target to $40

Benzinga·10/23/2025 21:02:15
Listen to the news
UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $70 to $40.